UT-MD Anderson Cancer Center: ASCO - HER2-Targeted Antibody Drug Conjugate Shows Strong Anti-Tumor Activity and Durable Responses Across Multiple Tumor Types
June 06, 2023
June 06, 2023
HOUSTON, Texas, June 6 (TNSres) -- The University of Texas's MD Anderson Cancer Center issued the following news release on June 5, 2023:
* * *
Trastuzumab deruxtecan could provide new treatment option for patients with hard-to-treat cancers
* * *
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from . . .
* * *
Trastuzumab deruxtecan could provide new treatment option for patients with hard-to-treat cancers
* * *
In a new study of trastuzumab deruxtecan, a HER2-targeted antibody drug conjugate, researchers observed encouraging responses and long-lasting clinical benefit in several tumor types. These data from . . .